Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) EBT Margin: 2012-2025

Historic EBT Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to -10.94%.

  • Ptc Therapeutics' EBT Margin rose 3886.00% to -10.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.40%, marking a year-over-year increase of 8486.00%. This contributed to the annual value of -74.22% for FY2024, which is 946.00% up from last year.
  • Per Ptc Therapeutics' latest filing, its EBT Margin stood at -10.94% for Q3 2025, which was up 72.47% from -39.72% recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' EBT Margin peaked at 79.06% during Q1 2025, and registered a low of -154.99% during Q4 2024.
  • In the last 3 years, Ptc Therapeutics' EBT Margin had a median value of -55.52% in 2023 and averaged -55.38%.
  • As far as peak fluctuations go, Ptc Therapeutics' EBT Margin surged by 13,999bps in 2021, and later crashed by 7,497bps in 2024.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' EBT Margin stood at -83.89% in 2021, then plummeted by 3,159bps to -115.48% in 2022, then surged by 3,547bps to -80.01% in 2023, then plummeted by 7,497bps to -154.99% in 2024, then spiked by 3,886bps to -10.94% in 2025.
  • Its EBT Margin stands at -10.94% for Q3 2025, versus -39.72% for Q2 2025 and 79.06% for Q1 2025.